Refractory Mycosis Fungoides Clinical Trials

13 clinical trials for Refractory Mycosis Fungoides across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma — RECRUITING · PHASE1
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma — RECRUITING · PHASE1
• A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab — RECRUITING
• Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides — RECRUITING
• Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Pembrolizumab (MK-3475) in Combination With Romidepsin — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment — TERMINATED · PHASE1
• Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas — COMPLETED · PHASE1
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer — TERMINATED · PHASE1
• Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides — COMPLETED · PHASE1
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma — TERMINATED · PHASE2
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas — WITHDRAWN · PHASE1

Refine this search